In the past week, APRE stock has gone up by 1.12%, with a monthly gain of 7.78% and a quarterly plunge of -17.81%. The volatility ratio for the week is 7.35%, and the volatility levels for the last 30 days are 4.57% for Aprea Therapeutics Inc The simple moving average for the past 20 days is 0.93% for APRE’s stock, with a -35.07% simple moving average for the past 200 days.
Is It Worth Investing in Aprea Therapeutics Inc (NASDAQ: APRE) Right Now?
Company’s 36-month beta value is 1.20.Analysts have differing opinions on the stock, with 1 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for APRE is 4.82M, and currently, short sellers hold a 1.53% ratio of that floaft. The average trading volume of APRE on June 26, 2025 was 28.00K shares.
APRE) stock’s latest price update
Aprea Therapeutics Inc (NASDAQ: APRE)’s stock price has soared by 10.09 in relation to previous closing price of 1.63. Nevertheless, the company has seen a gain of 1.12% in its stock price over the last five trading days. globenewswire.com reported 2025-06-25 that Preclinical data demonstrate potent single-agent and combination effects in head and neck squamous cell carcinoma (HNSCC) models, including synergy with anti–PD-1 therapy
Analysts’ Opinion of APRE
Berenberg, on the other hand, stated in their research note that they expect to see APRE reach a price target of $37. The rating they have provided for APRE stocks is “Buy” according to the report published on December 16th, 2020.
JP Morgan gave a rating of “Neutral” to APRE, setting the target price at $25 in the report published on September 29th of the previous year.
APRE Trading at 5.44% from the 50-Day Moving Average
After a stumble in the market that brought APRE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -64.07% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at APRE starting from Gilad Oren, who purchase 5,500 shares at the price of $1.84 back on Apr 03 ’25. After this action, Gilad Oren now owns 345,620 shares of Aprea Therapeutics Inc, valued at $10,110 using the latest closing price.
Duey Marc, the Director of Aprea Therapeutics Inc, sale 6,462 shares at $4.58 during a trade that took place back on Oct 18 ’24, which means that Duey Marc is holding 233,651 shares at $29,583 based on the most recent closing price.
Stock Fundamentals for APRE
Current profitability levels for the company are sitting at:
- -19.88 for the present operating margin
- 0.99 for the gross margin
The net margin for Aprea Therapeutics Inc stands at -18.35. The total capital return value is set at -0.9. Equity return is now at value -59.80, with -52.72 for asset returns.
Currently, EBITDA for the company is -12.94 million with net debt to EBITDA at 1.26. When we switch over and look at the enterprise to sales, we see a ratio of -12.14. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.90.
Conclusion
In a nutshell, Aprea Therapeutics Inc (APRE) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
